Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

An international serum standard for application in assays to detect human complement activation products.

Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE.

Mol Immunol. 2013 Dec 15;56(3):232-9. doi: 10.1016/j.molimm.2013.05.221. Epub 2013 Jun 17. Review. Erratum in: Mol Immunol. 2014 Aug;60(2):115.

PMID:
23787367
2.

Electroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard.

van Vuuren BJ, Bergseth G, Mollnes TE, Shaw AM.

J Immunol Methods. 2014 Jan 15;402(1-2):50-6. doi: 10.1016/j.jim.2013.11.010. Epub 2013 Nov 25.

PMID:
24287422
3.
4.

A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission.

Veszeli N, Füst G, Csuka D, Trauninger A, Bors L, Rozsa C, Nagy Z, Jobbágy Z, Eizler K, Prohászka Z, Varga L, Illes Z.

Mol Immunol. 2014 Feb;57(2):200-9. doi: 10.1016/j.molimm.2013.09.010. Epub 2013 Oct 26.

PMID:
24172223
5.

Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood.

Salvesen B, Nielsen EW, Harboe M, Saugstad OD, Mollnes TE.

Mol Immunol. 2009 Feb;46(4):688-94. doi: 10.1016/j.molimm.2008.09.001. Epub 2008 Oct 31.

PMID:
18950866
6.

Complement activation in patients with systemic lupus erythematosus without nephritis.

Mollnes TE, Haga HJ, Brun JG, Nielsen EW, Sjöholm A, Sturfeldt G, Mårtensson U, Bergh K, Rekvig OP.

Rheumatology (Oxford). 1999 Oct;38(10):933-40.

PMID:
10534542
7.

Quantitation of activation of the human terminal complement pathway by ELISA.

Sanders ME, Schmetz MA, Hammer CH, Frank MM, Joiner KA.

J Immunol Methods. 1985 Dec 27;85(2):245-56.

PMID:
2416846
8.

Complement activation by neutrophil granulocytes.

Asberg AE, Mollnes TE, Videm V.

Scand J Immunol. 2008 Apr;67(4):354-61. doi: 10.1111/j.1365-3083.2008.02077.x. Epub 2008 Feb 1.

9.

The release of C5a in complement-activated serum does not require C6.

Biesecker G, Wagner JL, Hugli TE.

J Immunol. 1989 Aug 15;143(4):1228-32.

PMID:
2545783
10.
11.
12.
13.

Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement.

Hugo F, Krämer S, Bhakdi S.

J Immunol Methods. 1987 May 20;99(2):243-51.

PMID:
3584995
14.

In vitro complement activation favoring soluble C5b-9 complex formation alters myocellular sodium homeostasis.

Wang W, Okamoto K, Rounds J, Chambers E, Jacobs DO.

Surgery. 2001 Feb;129(2):209-19.

PMID:
11174714
15.

High-dose intravenous immunoglobulin treatment activates complement in vivo.

Mollnes TE, Høgåsen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R.

Scand J Immunol. 1998 Sep;48(3):312-7.

17.

Complement activation in diabetic ketoacidosis and its treatment.

Jerath RS, Burek CL, Hoffman WH, Passmore GG.

Clin Immunol. 2005 Jul;116(1):11-7.

PMID:
15925827
19.

Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.

Brodeur JP, Ruddy S, Schwartz LB, Moxley G.

Arthritis Rheum. 1991 Dec;34(12):1531-7.

PMID:
1747138
20.

Complement analysis in the 21st century.

Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordoba S, Kirschfink M.

Mol Immunol. 2007 Sep;44(16):3838-49. Review.

PMID:
17768101

Supplemental Content

Support Center